We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+3.67%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$22.8B
AUM Growth
-$4.8M
Cap. Flow
+$69.6M
Cap. Flow %
0.31%
Top 10 Hldgs %
39.53%
Holding
188
New
24
Increased
37
Reduced
34
Closed
37

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$508M
2
CRM icon
Salesforce
CRM
+$266M
3
NOW icon
ServiceNow
NOW
+$264M
4
SPGI icon
S&P Global
SPGI
+$246M
5
SHW icon
Sherwin-Williams
SHW
+$212M

Sector Composition

Rank Sector Weight
1 Healthcare 33.98%
2 Technology 14.71%
3 Financials 12.17%
4 Communication Services 7.05%
5 Industrials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VYGR icon
76
Voyager Therapeutics
VYGR
$201M
$14.6M 0.06%
2,570,700
+278,700
+12% +$1.8M
TYRA icon
77
Tyra Biosciences
TYRA
$1.58B
$13.9M 0.06%
+1,000,981
New +$18.2M
TNGX icon
78
Tango Therapeutics
TNGX
$4.41B
$12.4M 0.05%
+4,000,000
New +$18.6M
ENTA icon
79
Enanta Pharmaceuticals
ENTA
$400M
$12.1M 0.05%
2,108,262
ARWR icon
80
Arrowhead Research
ARWR
$12.4B
$11.8M 0.05%
+628,800
New +$12.9M
NUVL
81
DELISTED
Nuvalent
NUVL
$11.7M 0.05%
150,000
GEHC icon
82
GE HealthCare
GEHC
$32.4B
$9.69M 0.04%
+124,000
New +$10.5M
MARA icon
83
Marathon Digital Holdings
MARA
$3.9B
$9.31M 0.04%
+555,000
New +$11.2M
BBOT
84
BridgeBio Oncology
BBOT
$747M
$6.3M 0.03%
600,000
BDSX icon
85
Biodesix
BDSX
$248M
$5.83M 0.03%
190,571
-41,269
-18% -$1.21M
DYN icon
86
Dyne Therapeutics
DYN
$4.9B
$5.4M 0.02%
229,121
-198,879
-46% -$5.88M
SLNO
87
DELISTED
Soleno Therapeutics
SLNO
$4.05M 0.02%
+90,000
New +$4.66M
GRND.WS
88
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$3.65M 0.02%
540,000
MTAL
89
DELISTED
Metals Acquisition
MTAL
$3.51M 0.02%
330,901
-79,296
-19% -$979K
VNET
90
VNET Group
VNET
$2.09B
$3.08M 0.01%
650,000
ALVO icon
91
Alvotech
ALVO
$1.29B
$2.64M 0.01%
199,675
JANX icon
92
Janux Therapeutics
JANX
$967M
$2.57M 0.01%
+48,000
New +$2.54M
SMC
93
Summit Midstream
SMC
$419M
$2.2M 0.01%
58,214
PRME icon
94
Prime Medicine
PRME
$559M
$2.19M 0.01%
750,000
ELEV
95
DELISTED
Elevation Oncology
ELEV
$1.98M 0.01%
3,527,482
GATE
96
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$1.65M 0.01%
150,000
MDGL icon
97
Madrigal Pharmaceuticals
MDGL
$11.8B
$1.02M ﹤0.01%
3,319
FBRX icon
98
Forte Biosciences
FBRX
$1.57B
$795K ﹤0.01%
35,000
-37,413
-52% -$445K
TVRD
99
Tvardi Therapeutics
TVRD
$23.4M
$794K ﹤0.01%
43,228
-1
-0% -$11
ROIV icon
100
Roivant Sciences
ROIV
$26.2B
$438K ﹤0.01%
37,000

Similar funds

Farallon Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Farallon Capital Management held 188 positions worth $22.8B, down 0.02% from $22.8B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Farallon Capital Management's Q4 2024 filing shows 24 new, 37 increased, 34 reduced and 37 closed positions. Its largest new stake was Autodesk: 1,841,800 shares worth $544M. The largest sale was CATALENT, INC., an estimated $508M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

  • Farallon Capital Management's largest Q4 2024 buy was Autodesk: 1,841,800 shares worth $544M.
  • Farallon Capital Management added most to Discover Financial Services in Q4 2024, an estimated $580M increase.
  • Farallon Capital Management's biggest Q4 2024 reduction was Salesforce, cutting an estimated $266M.
  • Farallon Capital Management fully exited CATALENT, INC. in Q4 2024, selling an estimated $508M.
  • Farallon Capital Management's ten largest holdings make up 40% of its $22.8B portfolio in Q4 2024.
  • Farallon Capital Management opened 24 new positions and closed 37 in Q4 2024.
  • Farallon Capital Management's portfolio value fell 0.02% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.